Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 50, Issue 4, Pages 349-356Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jjco/hyaa004
Keywords
PET; PET/CT; PSMA; prostate cancer; prostate-specific membrane antigen
Categories
Ask authors/readers for more resources
From a clinical perspective, prostate-specific membrane antigen (PSMA) is a valuable target for both diagnosis and radioligand therapy (RLT) of prostate cancer. The term 'specific' has been used to characterize a histologic hallmark of overexpression in the membrane of most prostate cancer. Many PSMA ligands have been developed since the previous decade and have been used in several clinical trials and clinical studies. However, procedure, specification, protocol, interpretation criteria, radiation dose, and cost-effectiveness of PSMA ligands have not been fully explained. Regardless of worldwide use of promising PSMA-ligand PET and RLT, it has not been approved in Japan. Expedited introduction of PSMA-ligand PET and RLT to Japan and implementation of clinical study are eager for many patients with prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available